and 1 other(s)
Background and Aim: Insulin pen devices address many of the concerns with vial and syringe therapy and have led to increased adherence. However, insulin pens do not address patient concerns of injection frequency, injection embarrassment or the inconvenience to carry supplies when away from home. A novel 24-hr wearable insulin delivery device (V-Go®) offers discreet basal-bolus insulin delivery, without the need for multiple daily injections or additional supplies. This analysis evaluated the clinical effectiveness of switching to V-Go for basal-bolus therapy and explored if baseline doses of basal or prandial insulin impacted the effectiveness of V-Go. Methods: Nine diabetes centers in the United States participated in this retrospective study using electronic medical records to extract data. Patients uncontrolled (A1C ≥ 7.0%) and prescribed basal-bolus therapy administered by pen devices prior to V-Go were included in the evaluation. Change in A1C and insulin dosing compared to baseline were evaluated and based on baseline basal and prandial doses (≤ 50 or > 50 U/day). Results: Patients (N=148) were evaluated. Mean baseline characteristics were A1C 9.1%, weight 218 lbs, insulin basal, prandial and total U/day were 47, 35 and 82, respectively. After 3 and 7 months of V-Go use, A1C and insulin doses were significantly reduced compared to baseline. Insulin needle sticks decreased from 4.2/day to 1/day with V-Go. Significant reductions in A1C and total insulin were also observed when stratified based on baseline dosing. Conclusion: Basal-bolus therapy with V-Go resulted in significant reductions in A1C and insulin compared to prior pen therapy.
No datasets are available for this submission.
No license information is available for this submission.